Anorexia News and Research RSS Feed - Anorexia News and Research

Eating Recovery Center collaborates with Eating Disorder Center at San Antonio

Eating Recovery Center (www.EatingRecoveryCenter.com), an international center providing comprehensive, specialized eating disorders treatment to female and male adults, adolescents and children, has partnered with the Eating Disorder Center at San Antonio (EDCASA). [More]
Brain disconnect leaves teen brain less able to judge trustworthiness

Brain disconnect leaves teen brain less able to judge trustworthiness

Making a snap decision usually means following your initial reaction -- going with your gut. That intuitive feeling sprouts from the limbic system, the evolutionarily older and simpler part of the brain that affects emotion, behavior and motivation. [More]
Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival. [More]

GW SPHHS to hold public forum on prevalence and impact of eating disorders

The George Washington (GW) University School of Public Health and Health Services (SPHHS) will hold a public forum on February 25 that will address the prevalence and impact of eating disorders, especially on college campuses. [More]
Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La. [More]
Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative. [More]
Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease. [More]
NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment. [More]
Study identifies patterns of brain activity associated with eating disorders

Study identifies patterns of brain activity associated with eating disorders

A growing body of evidence shows the impact of diet on brain function, and identifies patterns of brain activity associated with eating disorders such as binge eating and purging. The findings were presented at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health. [More]

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets. [More]
Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Researchers highlight presence of specific antibodies that regulate appetite in obese patients

Obesity affects more than 15% of adults in France, and its constitutive mechanisms are still not completely explained. Normally, fine control of weight and food intake is coordinated by a specialised part of the brain (the hypothalamus). [More]
Psychotherapy: New treatment choice for anorexia nervosa

Psychotherapy: New treatment choice for anorexia nervosa

A large-scale study has now shown that adult women with anorexia whose disorder is not too severe can be treated successfully on an out-patient basis. Even after conclusion of therapy, they continue to make significant weight gains. [More]
Skin cancer drug shows periocular promise

Skin cancer drug shows periocular promise

Early research suggests that patients with periocular basal cell carcinoma may benefit from treatment with a drug targeting the Hedgehog signaling pathway. [More]

Slow caress or stroke may play part in creating, sustaining positive sense of self

A loving touch, characterized by a slow caress or stroke - often an instinctive gesture from a mother to a child or between partners in romantic relationships - may increase the brain's ability to construct a sense of body ownership and, in turn, play a part in creating and sustaining a healthy sense of self. [More]
Binge eating disorder is different from anorexia nervosa and bulimia nervosa

Binge eating disorder is different from anorexia nervosa and bulimia nervosa

Food addiction is not yet recognised as a mental disorder but certain obese individuals clearly display addictive-like behaviour towards food. [More]

Two gene mutations associated with increased risk of developing eating disorders

Eating disorders like anorexia nervosa and bulimia often run in families, but identifying specific genes that increase a person's risk for these complex disorders has proved difficult. [More]

Study: Women with eating disorders are less likely to have children

Women with eating disorders are less likely to have children than others in the same age group, indicates a study conducted at the University of Helsinki, Finland. The likelihood for miscarriage was more than triple for binge-eating disorder (BED) sufferers and the likelihood of abortion more than double for bulimics than others in the same age group. [More]
UNC researchers find precise cellular connections responsible for triggering overeating

UNC researchers find precise cellular connections responsible for triggering overeating

Sixty years ago scientists could electrically stimulate a region of a mouse's brain causing the mouse to eat, whether hungry or not. Now researchers from UNC School of Medicine have pinpointed the precise cellular connections responsible for triggering that behavior. [More]

Study shows certain brain cells play critical role in anorexia, bulimia, and binge eating disorder

Sixty years ago scientists could electrically stimulate a region of a mouse's brain causing the mouse to eat, whether hungry or not. Now researchers from UNC School of Medicine have pinpointed the precise cellular connections responsible for triggering that behavior. [More]
Exposure to cocaine during in utero development causes disruptions in normal brain development

Exposure to cocaine during in utero development causes disruptions in normal brain development

Prenatal cocaine exposure affects both behavior and brain. Animal studies have shown that exposure to cocaine during in utero development causes numerous disruptions in normal brain development and negatively affects behavior from birth and into adulthood. [More]